Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
genipin 1-beta-D-gentiobioside
- Development stage
- Preclinical
- Lead developer
- Shanghai Institute of Materia Medica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Genipin 1-beta-D-gentiobioside is a natural iridoid glycoside primarily isolated from the fruit of Gardenia jasminoides (and also found in Genipa americana). It is a small-molecule research compound with reported hepatoprotective, anti-inflammatory, antioxidant, and antithrombotic activities. Recent preclinical research has demonstrated its potential in treating metabolic-associated steatohepatitis (MASH) by directly binding to and inhibiting the enzymatic activity of hepatic protein phosphatase 2A (PP2A). This inhibition leads to increased phosphorylation of acetyl-CoA carboxylase 1 (ACC1), thereby suppressing de novo lipogenesis and reducing hepatic lipid accumulation, inflammation, and early-stage fibrosis. It is not an approved drug and is currently sold for research use only.
- Other names
- genipin 1-O-beta-D-gentiobiosidegenipin1-O-beta-D-gentiobiosidegenipin-1-O-beta-D-gentiobiosidegenipin 1-beta-D-gentiobiosidegenipin1-beta-D-gentiobiosidegenipin-1-beta-D-gentiobiosidegenipin 1-beta-gentiobiosidegenipin1-beta-gentiobiosidegenipin-1-beta-gentiobiosidegenipin 1-gentiobiosidegenipin1-gentiobiosidegenipin-1-gentiobiosidegenipin gentiobioside
02
Targets
PP2A (Protein phosphatase 2A)
Beyond the preview
Go deeper on genipin 1-beta-D-gentiobioside.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on genipin 1-beta-D-gentiobioside.